Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COG trial results are published online today - this was a randomised controlled trial to compare gefitinib with placebo in previously treated patients with advanced oesophageal cancer.

450 patient oncology study published today in the lancet oncology

The primary publication from the COG trial has been published today, with OCTRU Lead Statistician, Susan Dutton heading up the publication.  The study concluded that the use of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not improve the overall survival, but has palliative benefits in a subgroup of these difficult-to-treat patients with short life expectancy. Future research should focus on identification of predictive biomarkers to identify this subgroup of benefiting patients.

 

Click here to access the publication